AIDS Treatment News logo      

September 18, 2009

Maturation inhibitor bevirimat is well tolerated and effective in predicted responders

"The HIV maturation inhibitor bevirimat was well tolerated in a 32-person study presented this week at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. While antiviral activity was not particularly impressive overall, a genotypic test can predict which patients are likely to respond well."

Read more in Aidsmap, September 18, 2009.